Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors

John M. Kirkwood, Ahmad Tarhini, Joseph A. Sparano, Prapti Patel, Joan H. Schiller, Maxwell T. Vergo, Al B. Benson, Hussein Tawbi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective adjuvant therapy, and draws comparisons between the adjuvant regimens that have found application in solid tumors.

Original languageEnglish (US)
Pages (from-to)27-43
Number of pages17
JournalCancer Treatment Reviews
Volume39
Issue number1
DOIs
StatePublished - Feb 2013

Fingerprint

Neoplasms
Therapeutics
Drug Therapy

Keywords

  • Adjuvant
  • Chemotherapy
  • Disease-free survival
  • Immunotherapy
  • Molecularly targeted therapy
  • Neoplasms
  • Progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Kirkwood, J. M., Tarhini, A., Sparano, J. A., Patel, P., Schiller, J. H., Vergo, M. T., ... Tawbi, H. (2013). Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treatment Reviews, 39(1), 27-43. https://doi.org/10.1016/j.ctrv.2012.03.007

Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. / Kirkwood, John M.; Tarhini, Ahmad; Sparano, Joseph A.; Patel, Prapti; Schiller, Joan H.; Vergo, Maxwell T.; Benson, Al B.; Tawbi, Hussein.

In: Cancer Treatment Reviews, Vol. 39, No. 1, 02.2013, p. 27-43.

Research output: Contribution to journalArticle

Kirkwood, JM, Tarhini, A, Sparano, JA, Patel, P, Schiller, JH, Vergo, MT, Benson, AB & Tawbi, H 2013, 'Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors', Cancer Treatment Reviews, vol. 39, no. 1, pp. 27-43. https://doi.org/10.1016/j.ctrv.2012.03.007
Kirkwood, John M. ; Tarhini, Ahmad ; Sparano, Joseph A. ; Patel, Prapti ; Schiller, Joan H. ; Vergo, Maxwell T. ; Benson, Al B. ; Tawbi, Hussein. / Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. In: Cancer Treatment Reviews. 2013 ; Vol. 39, No. 1. pp. 27-43.
@article{25e65edbe8b64634935053b454a6e7ef,
title = "Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors",
abstract = "Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective adjuvant therapy, and draws comparisons between the adjuvant regimens that have found application in solid tumors.",
keywords = "Adjuvant, Chemotherapy, Disease-free survival, Immunotherapy, Molecularly targeted therapy, Neoplasms, Progression-free survival",
author = "Kirkwood, {John M.} and Ahmad Tarhini and Sparano, {Joseph A.} and Prapti Patel and Schiller, {Joan H.} and Vergo, {Maxwell T.} and Benson, {Al B.} and Hussein Tawbi",
year = "2013",
month = "2",
doi = "10.1016/j.ctrv.2012.03.007",
language = "English (US)",
volume = "39",
pages = "27--43",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors

AU - Kirkwood, John M.

AU - Tarhini, Ahmad

AU - Sparano, Joseph A.

AU - Patel, Prapti

AU - Schiller, Joan H.

AU - Vergo, Maxwell T.

AU - Benson, Al B.

AU - Tawbi, Hussein

PY - 2013/2

Y1 - 2013/2

N2 - Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective adjuvant therapy, and draws comparisons between the adjuvant regimens that have found application in solid tumors.

AB - Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective adjuvant therapy, and draws comparisons between the adjuvant regimens that have found application in solid tumors.

KW - Adjuvant

KW - Chemotherapy

KW - Disease-free survival

KW - Immunotherapy

KW - Molecularly targeted therapy

KW - Neoplasms

KW - Progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=84869085064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869085064&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2012.03.007

DO - 10.1016/j.ctrv.2012.03.007

M3 - Article

C2 - 22520262

AN - SCOPUS:84869085064

VL - 39

SP - 27

EP - 43

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 1

ER -